Related references
Note: Only part of the references are listed.Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial
Yanan Zheng et al.
EUROPEAN JOURNAL OF CANCER (2020)
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure A Nonrandomized Clinical Trial
Xiangyu Zhang et al.
JAMA NETWORK OPEN (2020)
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
Chun-Yan Lan et al.
LANCET ONCOLOGY (2018)
Anti-angiogenic agents in ovarian cancer: past, present, and future
B. J. Monk et al.
ANNALS OF ONCOLOGY (2016)
Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
Hyo Jin Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
Frede Donskov et al.
BRITISH JOURNAL OF CANCER (2015)
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Andres M. Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2015)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
M. M. Cooney et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
